A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids

Trial Profile

A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs Dupilumab (Primary) ; Mometasone
  • Indications Nasal polyps
  • Focus Therapeutic Use
  • Acronyms SINUS-52
  • Sponsors Sanofi
  • Most Recent Events

    • 03 May 2018 According to a Regeneron media release, data from this trial is expected to be reported during 2018.
    • 18 Dec 2017 Planned primary completion date changed from 19 Nov 2018 to 27 Aug 2018.
    • 20 Nov 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top